Is taxane/platinum/5 fluorouracil superior to taxane/platinum alone and does docetaxel trump paclitaxel in induction therapy for locally advanced oral cavity cancers.

Simple item page
dc.contributor.authorNoronha, V
dc.contributor.authorPatil, V
dc.contributor.authorJoshi, A
dc.contributor.authorMuddu, V
dc.contributor.authorBhattacharjee, A
dc.contributor.authorJuvekar, S
dc.contributor.authorArya, S
dc.contributor.authorChaturvedi, P
dc.contributor.authorChaukar, D
dc.contributor.authorPai, P S
dc.contributor.authorDcruz, A K
dc.contributor.authorPrabhash, K
dc.date.accessioned2016-02-16T06:48:26Z
dc.date.available2016-02-16T06:48:26Z
dc.date.issued2015-01
dc.description.abstractBACKGROUND: Cisplatin and 5 fluorouracil drug combination is inferior to the combination of taxane with these 2 drugs. However, often in clinical practice at our center giving TPF (docetaxel, cisplatin, 5 fluorouracil) is difficult in view of logistics and tolerance issues. In such a scenario, we prefer to use the 2 drugs combination of platinum and taxane. However, no study has addressed whether a 2 drugs combination, which includes taxane is inferior to the 3 drugs combination and which the taxane of choice is in the 2 drugs combination of taxane and platinum. METHODS: This is a retrospective analysis of prospectively collected data of patients undergoing induction chemotherapy (IC) in oral cavity cancers from 2010 to 2012. We chose for analysis those patients who had a baseline scan done within 4 weeks of starting therapy and a follow‑up scan done within 2 weeks of completion of the second cycle of IC. Response was scored in accordance with RECIST version 1.1. Chi‑square analysis was done to compare response rates (RRs) between regimens. RESULTS: Two hundred and forty‑five patients were identified. The median age was 45 years (24–70 years), 208 (84.9%) were male patients, and 154 patients (62.9%) had primary in the Buccal mucosa. The regimens received were TPF 22 (9%), docetaxel + cisplatin 97 (39.6%), paclitaxel + cisplatin 89 (36.3%), docetaxel + carboplatin 16 (6.5%) and paclitaxel + carboplatin 21 (8.6%). The overall RRs were complete response, partial response, stable disease and progressive disease in 4 (1.6%), 56 (22.9%), 145 (59.2%) and 40 (16.3%). The 3 drugs regimen (TPF) had 50% RR as compared to 22% RR with 2 drugs regimen (P = 0.004). Docetaxel containing regimens had 30.3% RR as compared to 17.2% RR with paclitaxel containing regimens (P = 0.094). CONCLUSIONS: TPF has better RR than a 2 drugs taxane‑containing regimen and docetaxel leads to a better RR than paclitaxel for IC in locally advanced oral cavity cancers.en_US
dc.identifier.citationNoronha V, Patil V, Joshi A, Muddu V, Bhattacharjee A, Juvekar S, Arya S, Chaturvedi P, Chaukar D, Pai P S, Dcruz A K, Prabhash K. Is taxane/platinum/5 fluorouracil superior to taxane/platinum alone and does docetaxel trump paclitaxel in induction therapy for locally advanced oral cavity cancers. Indian Journal of Cancer. 2015 Jan-Mar; 52(1): 70-73.en_US
dc.identifier.issn0019-509X
dc.identifier.urihttps://imsear.searo.who.int/handle/123456789/173020
dc.language.isoenen_US
dc.source.urihttps://www.indianjcancer.com/article.asp?issn=0019-509X;year=2015;volume=52;issue=1;spage=70;epage=73;aulast=Noronhaen_US
dc.subject2 drugs regimenen_US
dc.subject3 drugs regimenen_US
dc.subjectinduction chemotherapyen_US
dc.subjectlocally advanced oral cancersen_US
dc.subjectresponseen_US
dc.titleIs taxane/platinum/5 fluorouracil superior to taxane/platinum alone and does docetaxel trump paclitaxel in induction therapy for locally advanced oral cavity cancers.en_US
dc.typeArticleen_US
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
ijc2015v52n1p70.pdf
Size:
317.24 KB
Format:
Adobe Portable Document Format
Description:
Original article
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Indian Journal of Cancer